EXTENDED REPORTS

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005

L Annemans^1,2,3, E Spaepen¹, M Gaskin⁴, M Bonnemaire⁵, V Malier⁵, T Gilbert⁶, G Nuki⁷

¹ IMS Health, Brussels, Belgium
² Department of Public Health, Ghent University, Ghent, Belgium
³ School of Pharmacy, Brussels University, Brussels, Belgium
⁴ IMS Health, London, UK
⁵ Ipsen, Paris, France
⁶ Ipsen, Milford, Massachusetts, USA
⁷ University of Edinburgh Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK

Professor L Annemans, Ghent University, Faculty of Medicine, Department of Public Health, Building A, 2nd Floor, De Pintelaan 185, 9000 Ghent, Belgium; Lieven.Annemans{at}UGent.be

Objective: To investigate and compare the prevalence, comorbidities and management of gout in practice in the UK and Germany.

Methods: A retrospective analysis of patients with gout, identified through the records of 2.5 million patients in UK general practices and 2.4 million patients attending GPs or internists in Germany, using the IMS Disease Analyzer.

Results: The prevalence of gout was 1.4% in the UK and Germany. Obesity was the most common comorbidity in the UK (27.7%), but in Germany the most common comorbidity was diabetes (25.9%). The prevalence of comorbidities tended to increase with serum uric acid (sUA) levels. There was a positive correlation between sUA level and the frequency of gout flares. Compared with those in whom sUA was <360 µmol/l (<6 mg/dl), odds ratios for a gout flare were 1.33 and 1.37 at sUA 360–420 µmol/l (6–7 mg/dl), and 2.15 and 2.48 at sUA >530 µmol/l ( >9 mg/dl) in the UK and Germany, respectively (p<0.01).

Conclusions: The prevalence of gout in practice in the UK and Germany in the years 2000–5 was 1.4%, consistent with previous UK data for 1990–9. Chronic comorbidities were common among patients with gout and included conditions associated with an increased risk for cardiovascular disease, such as obesity, diabetes and hypertension. The importance of regular monitoring of sUA in order to tailor gout treatment was highlighted by data from this study showing that patients with sUA levels 360 µmol/l (6 mg/dl) had an increased risk of gout flares.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Roddy, E., Mallen, C. D., Hider, S. L., Jordan, K. P. (2009). Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 0: kep332v1-kep332 [Abstract] [Full Text]  
• Krishnan, E. (2009). Hyperuricemia and Incident Heart Failure. Circ Heart Fail 2: 556-562 [Abstract] [Full Text]  
• Elliot, A J, Cross, K W, Fleming, D M (2009). Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann Rheum Dis 68: 1728-1733 [Abstract] [Full Text]  
• Riches, P. L., Wright, A. F., Ralston, S. H. (2009). Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet 18: R177-R184 [Abstract] [Full Text]  
• Doherty, M. (2009). New insights into the epidemiology of gout. Rheumatology (Oxford) 48: ii2-ii8 [Abstract] [Full Text]  
• Mak, A., Ho, R. C.-M., Tan, J. Y.-S., Teng, G. G., Lahiri, M., Lateef, A., Vasoo, S., Boey, M. L., Koh, D. R., Feng, P. H. (2009). Atherogenic serum lipid profile is an independent predictor for gouty flares in patients with gouty arthropathy. Rheumatology (Oxford) 48: 262-265 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Sleep apnea - the missing gout comorbidity

Burton Abrams

Ann Rheum Dis Online, 11 Nov 2007 [Full text]